This observational study compares the efficacy and incidence of side-effects between dl-norgestrel (2 mg) and levonorgestrel (1 mg) associated with ethinyl oestradiol (200 |ig) given in two doses 12 h apart for emergency postcoital contraception. A total of 117 consecutive women were given dl-norgestrel in combination with the oestrogen (dl-norgestrel group) while 423 consecutive subjects received the combination ethinyl oestradiol/levonorgestrel (levonorgestrel group). Overall, four (0.8%) pregnancies occurred in the 540 treated women, one (0.9%) in the dl-norgestrel group and three (0.7%) in the levonorgestrel group. In addition to this similar high contraceptive efficacy between both study groups, women in the levonorgestrel group had a significantly lower incidence of side-effects (23.5%) and better timing of the next menstruation after treatment (75% had bleeding on time) than those in the dl-norgestrel group (corresponding figures were 50.5 and 62.6% respectively). It is concluded that levonorgestrel should be used in preference to dl-norgestrel for post-coital contraception in the Yuzpe regimen.
Introduction
At present, the need for increasing awareness and availability of, and access to, emergency contraception is a matter of great concern (Cayley, 1995; Lancet, 1995; Pearson et al., 1995; Pillaye, 1995) . Post-coital or emergency contraception is a simple, safe, and effective strategy that has several obstacles to overcome before its full potential is realized. The most daunting, despite experience spanning decades, is continued ignorance of this approach among healthcare personnel as well as potential users (Lancet, 1995) . The other major drawback for the widespread use of post-coital contraception is that a strong belief persists, not only among potential users but also among doctors, that such contraception is associated with frequent and severe side-effects (Cayley, 1995) .
•Alternative notation DL © European Society for Human Reproduction and Embryology Yuzpe and Lancee (1977) and Yuzpe et al. (1982) initially described the currently most commonly-accepted hormonal method of post-coital contraception. These authors used the combination of 200 u.g ethinyl oestradiol and 2 mg dl-norgestrel given in two divided doses, 12 h apart, within 72 h of unprotected intercourse. The pregnancy rate was 1.6% but there was a relatively high incidence of side-effects (-50% of cases), mainly nausea and/or vomiting, which may decrease patients' compliance. Therefore, although the Yuzpe regimen has become an accepted and recommended method of postcoital contraception, there is a need to reduce the incidence of gastrointestinal effects while maintaining efficacy.
A few studies with the Yuzpe method (Hoffman et al, 1987; Ho and Kwan, 1993) have used 1 mg levonorgestrel in preference to 2 mg dl-norgestrel on the basis that biologically the two formulations are presumed to be equivalent. The dl-form is a racemic mixture containing 50% of the inactive dextrorotatory enantiomer and 50% of the active levorotatory enantiomer, hence the double dosage with dl-norgestrel (Jones et al, 1979) . As the inactive isomer has to be metabolized however, it should be considered preferable to use pure levonorgestrel. Curiously, however, there are no studies specifically comparing the efficacy and tolerance of dl-norgestrel and levonorgestrel associated with ethinyl oestradiol in the Yuzpe regimen. Furthermore, die only hormonal treatment specifically licensed for post-coital contraception is Schenng's PC4 (UK and New Zealand) or Tetragynon (Germany, Switzerland, Sweden, South Africa) (Lumb, 1994) but while PC4 consists of four tablets each containing 50 u.g ethinyl oestradiol and 0.50 mg dl-norgestrel, Tetragynon contains four tablets of ethinyl oestradiol 50 )Xg and levonorgestrel 250 (xg. Similarly, while recent reviews (Fasoli et al., 1989; Silvestre et al., 1991) , studies (Glasier et al, 1992) and books on endocrine therapy (Rivlin, 1990; Henzl, 1991) consider dl-norgestrel for the Yuzpe regimen, others consider levonorgestrel (Hoffman et al., 1987; Ho and Kwan, 1993; Speroff et al, 1994; Ginsburg, 1996) and still some authors consider that both progestogens can be used indistinctly (Fathalla et al, 1990 ).
The present report shows that ethinyl oestradiol plus levonorgestrel in the Yuzpe regimen is associated with a significantly lower incidence of side-effects than the combination ethinyl estradiol/dl-norgestrel while maintaining the contraceptive efficacy.
Materials and methods
The 540 study subjects ranging in age from 15-43 years were recruited from women attending the Diatros Family Planning Center,
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Downloaded from https://academic.oup.com/humrep/article-abstract/11/11/2449/575548 by guest on 11 January 2019 Barcelona, Spain, for post-coital contraception. They were consecutive patients strictly fulfilling the following inclusion criteria: (i) the subjects were healthy and had no medical contraindication to the oestrogen-progestogen regimen; (ii) they were seen within 72 h after a single act of unprotected intercourse and were willing to use a condom or abstain from intercourse for the rest of current cycle; (iii) all had regular menstrual cycles of 28 + 7 Hays, including the preceding 3 months; (iv) all had sexual intercourse during the potenually fertile phase of the cycle which was calculated as the average cycle length of each woman minus 14 days ± 3 No patient had been pregnant nor had been using hormonal treatment or regular prescription drugs in the previous three months. The study protocol was approved by the review board of the Diatros Family Planning Center of Barcelona.
From January 1988 to August 1990, all the 117 women seeking emergency contraception and fulfilling the above inclusion criteria were given two tablets of combined contraceptive pills each containing 50 u.g of ethinyl oestradiol and 0.50 mg dl-norgestrel (Eugynon; Schenng Espafla SA, Madrid, Spain) (dl-norgestrel group) on admission to the study, and another two tablets 12 h later. Increasing awareness on the usefulness of levonorgestrel for hormonal contraception and FIGO's observation that dl-norgestrel and levonorgestrel associated with ethinyl oestradiol could be used indistinctly in postcoital contraception (Fathalla et al., 1990) , led us to use the latter progestogen Thus, from September 1990 to December 1995, all the 423 women requesting post-coital contraception and fulfilling the inclusion criteria received four tablets of combined contraceptive pills each containing 50 u.g of ethinyloestradiol and 0.25 mg levonorgestrel (Neogynona; Schenng Espafia) (levonorgestrel group) given in two doses 12 h apart. No other medication was given. Women who vomited <2 h after taking a set of pills were given two additional tablets. This occurred after the second dose of medication in two and three women, respectively, in the dl-norgestrel and levonorgestrel groups.
Each patient was given a diary card to record the occurrence of side-effects and menstruation, and each made an appointment to return to the clinic within 2-3 weeks after treatment to assess the outcome. At the follow-up visit the diary card and date of menstrual bleeding were checked by a member of the clinic staff. If patients failed their follow-up appointment, phone or letter contact was made. The above inclusion criteria and overall management of candidates for emergency contraception remained constant throughout both study periods.
Statistical comparisons were performed with the x 2 test and the Yates correction when appropriate. Significance was defined as
Results
The patient characteristics of the two groups are shown in Table I . Patients in the levonorgestrel group tended to be younger and to attend the family planning clinic earlieT after unprotected intercourse than women in the dl-norgestrel group. However, most patients in both groups were 19-35 years old and attended the clinic 12-24 h after unprotected coitus. Menstrual cycle length, percentage of patients with a previous pregnancy, and interval between coitus and last menstrual period were similar in both groups studied. The most common reasons for requesting emergency post-coital contraception in both groups of subejcts were accidents with condoms (49% in the dl-norgestrel group and 56% in the levonorgestrel group) and unprotected intercourse (28 and 27% in the dl-norgestrel 2450 and levonorgestrel groups respectively). Other reasons were failures of a barrier method or coitus interruptus, IUD displacement and violation.
Results of post-coital contraception are summarized in Table II . A total of 490 women and adolescents returned completed diary cards. All side-effects were more frequent among the subjects treated with dl-norgestrel, and 76.5% of the women in the levonorgestrel group reported having no side-effects, a figure which is significantly higher than the 49.5% observed in the dl-norgestrel group {P <0.001). Nausea and/or vomiting were the most frequently reported complaints. Other side-effects included abdominal pain or bloating, intermenstrual spotting, dizziness, lethargy, and malaise and fatigue.
The distribution of delays between coitus and treatment was significantly different for the two groups studied (Table I ) and the monthly rate of recruitment into the second, levonorgestrel variant was almost double the rate of recruitment in the first 32 months when dl-norgestrel was in use (6.6 versus 3.6 per month). Therefore, in order to exclude that the observed differences between treatments may reflect better knowledge and acceptance of the method among women or result from differences in time to treatment, we compared the incidence of side-effects within each time to treatment period and over each consecutive 8 month period (Tables IH and IV) . Incidence of side-effects was significantly higher in the dl-norgestrel group irrespective of time to treatment but the distribution of side-effects was similar in both groups of treatment (Table  HI) . Furthermore, there was significant variability neither in the experience of side-effects nor in the time from coitus to treatment during each treatment period. However, there was a trend (P = 0.05) for women treated with levonorgestrel to present earlier following intercourse throughout the study period (Table IV) .
All the 50 women who did not return to the clinic for the follow-up visit immediately after the treatment cycle were contacted later in order to know the efficacy of treatment. Altogether, there was one pregnancy (0.9%) in the dl-norgestrel group and three (0 7%) in the levonorgestrel group. These failure rates were not statistically different. All the pregnancies were intrauterine as shown by ultrasonographic examination. The timing of the onset of menstrual bleeding after postcoital contraception in the two groups studied is shown in Table H A woman who reported bleeding within 3 days before or after the expected day of menstruation was described as having menstruated on time. Levonorgestrel had less effect on timing of next menstruation with 75% of women bleeding around the expected time and less subjects bleeding early or late (differences with dl-norgestrel group almost reaching statistical significance, P = 0.05). Menses considered to be on tune were those that occurred between 3 days before or after the expected date NS = not significant Discussion The Yuzpe method was originally defined as a combination of 100 (ig ethinyl oestradiol and 1 mg dl-norgestrel given within 72 h after a single exposure to unprotected intercourse and repeated 12 h later (Yuzpe and Lancee, 1977) . Our results show that both dl-norgestrel (2 mg) and levonorgestrel (1 mg) associated with ethinyl oestradiol are effective methods of emergency post-coital contraception as the overall failure rate was ~1% in a large population of women significantly at risk of unplanned pregnancy. This failure rate is similar to the 1.6% reported by Yuzpe et al. (1982) in their early studies and the 1.8 and 1.4% found in two recent reviews on the subject (Fasoli et al, 1989; Silvestre et al, 1991) . Also, results in the present study are in agreement with the 1.3% failure rate for the combined method with ethinyl oestradiol/levonorgestrel found by Hoffman et al. (1987) among 2883 applications. In most previous studies, however, treatment was administered regardless of the time in the cycle at which exposure occurred. This is in contrast to the present report where the treatment was limited to women having coitus on days -3 to +3 of the cycle. Our results are remarkable considering that not all women given emergency post-coital contraception are genuinely at risk for pregnancy, since unprotected intercourse that occurs in the early follicular phase or in the luteal phase of the cycle is unlikely to result in conception. Considering that the probability of pregnancy from a single act of coitus at any time in the cycle, in a regularly cycling woman, is estimated to be between 1:25 and 1:50 (Tietze, 1960) , in the 540 regularly cycling women included in our study the expected number of pregnancies would have been between 11 and 22. In our protocol study, however, only patients having unprotected intercourse at mid-cycle were included. An expected pregnancy rate of 0.10-0.15 after a single coitus in the fertile phase of the cycle (i.e. the cycle week ranging from days -3 to day + 3) has been calculated (Barrett and Marshall, 1969; Dixon et al., 1980; Guillebaud, 1993 ). This appears to be a more accurate estimate of the expected pregnancy rate in our study, in which one would have expected to see 54-81 pregnancies. The four pregnancies observed in this report represent a significant reduction (>90%) and this confirms the usefulness of the method. (40) 19 (53) 17 (51) 20 (77) 48 (89) 27 (79) 15 (79) 38 (76) 33 (82) 60 (80) 67 (72) J*l 2(40) 15 (60) 17 (47) 16 (48) 6 (23) 6(11) 7 (20) 4 (21) 12 (24) 7 (17) 15 (20) 26 (28) time to treatment Nausea and/or vomiting 2(40) 10 (40) 10 (28) 13 (39) 4 (15) 5(9) 4(12) 2 (10) 8 (16) 5(12) 10 (13) 18 (19) penod in the two groups (52) 13 (36) 8 (24) 4 (15) 6 (11) 6 (17) 3 (16) 8 (16) 5(12) 16 (21) 18 (19) period Hours coitus to treatment (n, %) b «24h 3(60) 11 (44) 22 (61) 20 (60) 12 (46) 40 (74) 27 (79) 8 (42) 35 (70) 29 (72) 55 (73) 64 (69) >24-48h
1 (20) 8 (32) 9 (25) 8 (24) 10 (38) 9 (17) 5 (15) 7 (37) 12 (24) 8 (20) 17 (23) 15 (16) >48 1 (20) 6 (24) 5 (14) 5 (15) 4 (15) 5 (9) 2 (6) 4 (21) 3 (6) 3 (7) 3 (4) 14 (15) •Not significant for vanabihty during each treatment penod. ''Not significant for vanability during dl-norgestrel treatment period, P • 0.05 during levonorgestrel treatment period.
The most frequent side-effects reported with the combined oestrogen/progestagen method for post-coital contraception are nausea and vomiting. Overall incidence and distribution of different side-effects in the dl-norgestrel group were very similar to those originally reported by Yuzpe et al. (1982) and are in agreement with results found in a recent review on the subject (Haspels, 1994) . However, a striking feature of our study is the significantly lower incidence of unwanted sideeffects in the levonorgestrel group which could not be explained by changes in patterns of contraceptive use, awareness or acceptance among the community. A plausible explanation is the fact that different progestogens serve as prodrugs and are transformed biochemically prior to manifesting their biological effects. Thus, it has been shown the existence of stereoselective biotransformations of dl-norgestrel and its enantiomers (Stanczyk and Roy, 1990) .
Norgestrel was first isolated as a racemic mixture [(±)-13p-ethyl-17p > -hydroxygon-4-en-3-on] which contained 50% of the dextrorotatory enantiomer and 50% of the levorotatory enantiomer. These enantiomers are mirror images of each other and are identical in all their physical properties, with the exception that they rotate the plane of polarized light in opposite directions. To distinguish between the two enantiomers, chemists have assigned, by convention, the prefix (d), or me sign (+) to die dextrorotatory form, and (1) or (-) to the levorotatory form; the racemic mixture is desginated by (dl) or (±). The biological activity of norgestrel resides in the levorotatory enantiomer (Stanczyk and Roy, 1990 ).
An alternate system for defining steroid configuration was proposed by Reichstein (Lardon et al., 1959) . In this system, a steroid is defined as belonging to the J-series of steroids if it has die same configuration as carbon-10 of cholesterol. If a steroid has die opposite configuration at this centre, it is classified in the /-series. On die basis of Reichstein's classification, die biologically active enantiomer of norgestrel belongs to the d series. It is important to realize that the d-and /-prefixes (italicized) refer only to die absolute configuration of a compound, in contrast to the d-and 1-prefixes (non-italicized) 2452 which refer to a compound's optical rotatory properties (Stanczyk and Roy, 1990) .
As stressed by Stanczyk and Roy (1990) investigators have frequently confused the stereochemical prefixes in die Reichstein (d, I) widi die prefixes used for optical isomers (d, 1). In publications, biologically active levonorgestrel has been referred to as d-norgestrel instead of rf-norgestrel, leading readers to believe that the biological activity of norgestrel resides in die dextrorotatory enantiomer. In order to clarify die confusion arising from die different designations assigned to norgestrel and its enantiomers in the literature, die World Healdi Organization selected die name, levonorgestrel, for the biologically active enantiomer of norgestrel. The name, norgestrel, for me racemic mixture of the compound remained the same. Its biologically inactive enantiomer was not assigned a new name and has been referred to as die dextrorotatory enantiomer of norgestrel (Stanczyk and Roy, 1990) .
Because of one of die two enantiomers of norgestrel is devoid of hormonal properties, administration of 0.5 mg of racemic mixture of the progestagen has been considered in many reports as equivalent to 0.25 mg levonorgestrel. However, it has been shown mat die racemate and its enantiomeric forms have different physical and biological properties as well as different metabolic disposition. Several in vivo studies have been carried out on die metabolism of die racemic mixture of norgestrel and its enantiomers, yet mere are still some unidentified metabolites (Stanczyk and Roy, 1990 ) However, it seems clear mat excretion by urine and faeces and die pattern of metabolites in plasma (both quantitatively and qualitatively) for die racemate and its enantiomers are quite different Therefore, some direct effects of die progestagen and/or its interaction witii hepatic/gastrointestinal disturbances induced by ediinyl oestradiol may be different for dl-norgestrel and levonorgestrel.
Treatment success in post-coital contraception is indicated by die onset of menses. Delay in the onset of die next menstrual period is an occurrence diat would undoubtedly be stressful to a woman who was worried diat she might be pregnant In this regard our study shows that more of the women in the levonorgestrel group had menses on time in the treatment cycle than subjects in the dl-norgestrel group, difference almost reaching statistical significance.
In conclusion, the present report shows that the combination ethinyl estradiol/levonorgestrel is as effective as ethinyl oestradiol in association with dl-norgestrel for emergency post-coital contraception but the former combination is associated with lower incidence of side-effects and better timing of next menses after treatment Further prospective, randomized studies would be desirable to confirm our findings; if so, then levonorgestrel should be used in preference to dl-norgestrel in the Yuzpe regimen. Tietze, C. (1960) Received on May 7, 1996 , accepted on September 6, 1996 
